K. Miller

Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases

K. Miller, Lewis J. Fermaglich, Janet Maynard, 2021, Orphanet Journal of Rare Diseases.

Investigating the landscape of US orphan product approvals

Michael L Lanthier, K. Miller, K. L. Miller, 2018, Orphanet Journal of Rare Diseases.

Value Assessment in the Regulatory Context.

J. Woodcock, K. Miller, K. L. Miller, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

New Opioid Analgesic Approvals and Outpatient Utilization of Opioid Analgesics in the United States, 1997 through 2015

J. Xu, P. Lurie, G. D. Dal Pan, 2018, Anesthesiology.

Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals

G. D. Dal Pan, Michael L Lanthier, K. Miller, 2017, Drug Safety.

An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.

J. Woodcock, Michael L Lanthier, K. Miller, 2013, Health affairs.

Trends In Orphan New Molecular Entities, 1983-2014: Half Were First In Class, And Rare Cancers Were The Most Frequent Target.

Michael L Lanthier, K. Miller, K. L. Miller, 2016, Health affairs.

Professional Values in Baccalaureate Nursing Students

K. Miller, Hope E Caldwell, K. L. Miller, 2016 .

Is the priority review voucher program stimulating new drug development for tropical diseases?

K. Miller, K. Kerr, Thomas Henry, 2018, PLoS neglected tropical diseases.

Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies

K. Miller, Lewis J. Fermaglich, A. Ipe, 2021, Expert opinion on orphan drugs.

Do investors value the FDA orphan drug designation?

K. Miller, K. L. Miller, 2017, Orphanet Journal of Rare Diseases.